Drug Profile
NN 8209
Alternative Names: Anti-C5aR-151; NN-8209; NNC 0151; NNC 0151-0000-0000Latest Information Update: 05 Sep 2014
Price :
$50
*
At a glance
- Originator Argos Therapeutics Inc
- Developer Novo Nordisk
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 30 Sep 2013 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Netherlands (Parenteral)
- 30 Sep 2013 Discontinued - Phase-II for Rheumatoid arthritis in Denmark, Czech Republic, Poland, Romania, United Kingdom and Hungary (SC)
- 11 Feb 2013 Novo Nordisk completes a phase II trial in Rheumatoid arthritis in European Union (NCT01223911)